►
From YouTube: Open Source Antibiotics Science Update Mar 19 2021
Description
Weekly open project meeting for Open Source Antibiotics Series 2.
Full Project: https://github.com/opensourceantibiotics/Series-2-Diarylimidazoles
Relevant GitHub Issue: https://github.com/opensourceantibiotics/Series-2-Diarylimidazoles/issues/61
On the call: Professor Matthew Todd, Dr Dana Klug, Giada Sabatino, Dr Lori Ferrins (Northeastern University), Dr Ben Perry (DNDi), Anthony Sama (citizen scientist), Dr Chris Swain (Cambridge MedChem Consulting), Matt Robinson (PostERA)
A
Okay,
all
right
hi,
everybody
welcome
to
open
source
antibiotics
series
2
meeting
on
friday,
19th
of
march.
We
just
have
a
few
things
to
talk
about
this
week.
I
think,
because
we
are
still
in
search
of
our
selectivity
window
between
compounds
that
are
potent
so
looking
for
composite
opponent
versus
mercer
and
compounds
that
are
non-toxic
and
so
we've
shipped
the
well.
We
shipped
down
the
corridor,
some
compounds
to
the
chat,
slime
lab
alex
and
the
shot
sign
lab
who
presented
recently
and
she's
looking
at
those.
A
So
we
I
mean
we
haven't
done
a
lot
of
chemistry,
also
because
I
think
that
dana
is
looking
at
something
else
right
now
and
ed
is
still
in
australia
and
can't
operate
in
the
lab
from
thousands
of
miles
away.
So
we,
our
chemistry,
is
low
from
the
chemistry
we've
done
in
our
lab,
but
there
are
some
shipments
going
on
which
I
just
wanted
to
catch
up
on,
just
to
make
sure
that
we're
all
on
the
on
the
same
page.
A
So
the
first
one
is:
is
this
stuff
about
some
compounds
that
already
exist
in
the
in
laurie's
collaboration
with
the
ndi?
Again,
please,
please
correct
me
using
their
own
words
here,
but
compounds
that
are
obviously
targeted
against
leash,
which
are
you
know
potential
here
and
so
we're
talking
about
getting
some
of
these
compounds.
A
Gamma's
going
both
ways,
so
so
these
are
the
one
I
guess
we
were
talking
about.
We
know
which
of
the
compounds
we
we
would
be
able
to
send
over.
So
this
is
first
of
all.
This
is
a
really
great
offer.
Thank
you
for
offering
to
take
these
compounds
in
and
get
them
evaluated,
because
we
can
get
a
bunch
of
tox
stuff
as
well
as
the
as
well
as
the
pathogen
assays,
which
is
great,
and
I
guess
that
goes
from
wrong.
B
A
B
C
Can
I
just
make
a
quick
one
yeah,
just
a
quick
comment
on
this?
If,
if
we
set
any
of
the
compounds
that
you
send
here
just
this
is
just
for
information,
but
they'll
go
to
antwerp,
they'll
be
tested
against
leash
money
and
phantom
trapezoid
cruisey,
two
strains
of
trapezoid
ci
pmm
background
cell
line
cytotoxicity
and
mrc5
background
cell
lines,
oxide
toxicity
as
standard,
so
you'll
get
2d
you'll
get
a
mouse
macrophage
and
also
a
human
cell
lined
tight
side
to
top
of
this
regardless.
D
C
A
C
C
A
Yeah,
I
don't
think
it'd
be
worth
it
to
be
honest,
just
much
better
to
get
this
going.
I
mean
that's
true
too,
but
that
is
very
much
so
true.
What's
the
so
I'm
sorry,
I
should
have
looked
at
this
color,
but
you've
got
the
the
ones
in
green,
the
ones
with
the
first
round
of
talks
right
great
okay
are
my
eyes
to
see
me.
Are
there
blues
and
blacks
there
right.
D
So
I
thought
maybe
those
would
be
a
bit
more
interesting
than
the
ones
that
are
not
active
but
happy
to
send
anything
because
obviously
chagas
unleash
is
not
necessarily
related
to
mrsa
activity,
so
it
might
potentially
be
interesting
for
that.
But
in
terms
of
the
talks,
I
guess
probably
we'd
be
a
bit
more
interested
in
the
ones
that
are
active.
A
C
B
C
Cytotoxicity
in
these
things,
it's
almost
certainly
going
to
be
because
of
the
by
dentate
yeah
nature
of
the
two.
So
it's
not
the
so
it's
it's
it's
the
it's
I
mean
depending
on
which
way
you
look
at
it,
it's
the
presence
of
the
two
period.
So
what
will
be
really
interesting
in
this
one
is
that
you
know.
Does
that
if
you
see,
if
you
see
cytotox,
that
is
and
what
what
if
I'm
well,
I
would
bet
money.
Are
you
seeing
side
talks?
C
But
the
question
is
how
big
is
the
window
when,
but
when
you
switch
to
compounds
like
mustache,
the
sixth
one
across
eight
three,
four
that
doesn't
have
a
two
periodic
one
just
down
down
into
the
right,
no
peridot,
you
know
those
you
should
see
be
really
if
any
of
any
of
those
turn
up
with
some
potency
against.
I
guess.
D
F
D
C
C
A
C
G
A
D
A
Okay,
but
thanks
for
doing
that,
I
know
it's,
it's
really
frustrating,
but
that's
just
the
way
it
is
all
right
and
so
yeah
the
cytox
is,
is
coming
in
we're
not
doing
anything
on
the
the
hyper
stuff.
That's
been
sent
in
yeah,
because
of
course,
we've
just
been
busy
with
everything
else,
and
I
think
that
was
it.
So
there
was
other
discussion
laureen
dana.
G
C
G
G
G
G
G
So
yeah
there's
only
a
few,
but
we
also
went
through.
I
went
through
and
actually
had
a
look
at
everything
that
we
have
made
in
support
of
the
project
that
we
actually
have
a
decent
amount
of,
and
so
one
of
the
other
things
that
I
can
do.
It's
that
one
will
that's
going
to
be.
A
work
in
progress
is
actually
go
through
and
look
at
that
set
of
compounds
there's
a
number
in
there
that
I
think,
could
be
really
interesting.
G
They
have
the
nh
they're,
not
an
alcohol
at
the
moment,
but
I
have
a
an
undergraduate
that
I
could
potentially
put
on
that
over
the
summer.
I
don't
know
what
month
the
summer
is.
Someone
else
can
help
me
with
that,
but
yeah
so,
but
basically
get
the
analytical
derivatives,
given
that
they
seem
to
be
the
most
interesting
in
terms
of
this
part
of
the
project
and
get
those
tested.
A
H
Oh
yeah,
I
mean
I
just
gave
an
example.
I
was
trying
to
go
over
the
sar
tables
last
night,
but
I
couldn't
quite
find
what
like
the
most
interesting
follow-up
compounds
were
for
you
all,
but
yeah.
If
you
all
need
help
just
finding
like
screening
compounds,
you
may
be
able
to
just
purchase
and
not
do
a
lot
of
work
on
building
blocks.
You
know
I
deal
with
these
problems
all
the
time.
So
so,
if
anyone
needs
an
account,
just
let
me
know.
B
A
H
A
Okay,
scientifically,
thank
you
very
much
for
this.
It's
very
useful.
I
mean
one
of
the
things
I
guess
we
were
trying
to
emphasize
in
the
discussion
was
that
we
need
to
keep
an
eye
on
this.
You
know
and
as
we
start,
if
we
start
changing
cores
or
changing
compounds,
so
we
need
to
redo
these
searches
because
they're,
you
know
they
they
get
out
of
date
and
if
we
scaffold
hot,
then
we
have
to
redo
searches.
H
A
H
Yeah,
I
mean
I'd,
say
it's
of
most
use
for
y'all
when
you
do
like
scaffold
hops,
maybe
and
then
before
really
digging
into
the
series.
I
know
like
enamine
real
if
you
switch
to
an
amide
beyond
that
anion
linkage,
there's
like
hundreds,
so
you
could
just
really
quickly
analog
before
you
start
doing
custom
synthesis.
H
C
H
A
Yeah,
so
this
was
an
ongoing
thing
about
the
fact
that
our
I
think
we're
talking
about
the
so
the
yeah,
the
google
street.
We
have
with
other
models
and
it
is
not.
It's
not
picked
up
on
searches.
If
you
go
in
there
with
inches
and
smiles
and
stuff,
we
don't,
we
don't
get
hits
on
our
own
spreadsheet.
We
were
looking
into
why
that
is
and-
and
there
was
a
solution
that
was
progressing
its
way
through
and
chris
swain
who's
on.
The
call
was
interesting.
E
A
Just
seems
curious
there.
You
know,
I
mean
your
github
repo.
Is
it
indexed
if
it's
a
public
repo
yeah,
so
the
github
repo
is
fine,
but
but
the
the
everything
in
there
is
findable,
no
problem,
that's
one
of
the
most
useful
things.
Is
you
find
stuff
you're
working
on
by
doing
the
google
search,
but
but
you'd
think
that
the
sheet
the
google
sheet
itself
will
be
indexed,
but
isn't
it
good.
A
Yeah
we
we,
we
have
also
mixed
success
with
the
lab
notebook
that
we
have
as
well,
which
sometimes
seems
to
work
and
sometimes
doesn't
work,
or
at
least
so,
when
you
put
the
smiles
in
the
inchi
in
the
lab
notebook
lab
archives
in
this
case,
and
you
make
it
publicly
available,
I
think
it's,
I
think,
that's
being
found.
So
if
you
just
put
it,
you
know
you
paste
in
the
inchi
key
or
something
you
get
it.
It
is
interestingly
low
down
the
page.
A
A
Right,
I
mean
essentially
you
know
we
want
to
make
sure
that
if
we're
working
on
a
molecule
it's
discovered
and
in
the
case
of
the
lab
notebooks,
then
when
you
draw
the
molecule
it
doesn't
perceive
what
it
is
yet
so
that
that
feature
isn't
enabled
in
our
elm
it's
good
in
other
ways,
but
in
that
way
in
the
in
the
chemical
metadata
is
not
good,
so
you
have
to
manually
paste
them
in
and
then
it's
fine,
then
you
can
find
it,
but
it
would
be
nice
if
that
works.
It'd
be
nice.
A
If,
if
our
compound
registration
thing
worked
better,
I
mean
the
the
google
sheet
has
this
advantage,
just
that
it's
very
straightforward
and
everyone
can
add
things
and
it's
very
easy
to
do
things,
whether
because
you
can
use
that
export
as
an
excel,
but
but
we've
never
invested
in
a
compound
registration
system
and
that's
the
step
we
never
took.
We
didn't
have
funds
for
it.
A
A
Well,
hang
on,
the
compounds
are
changing,
and
that
means
that
our
predictive
models
for
what
you're
going
to
make
next
are
changing
and
we
had
to
point
out
the
the
two
smiles
were
different,
but
they
were
just
tautomers
of
the
same
compound,
which
is
a
common
problem
with
smiles
right
is
that
you
can
get
these
these
uncertainties
and
it
changes
of
course,
the
way
the
compound
is
handled,
even
though
the
molecule
is
actually
the
same.
I
mean
we've
never
had
a
good
resolution
for
that.
I
don't
think
we
just.
A
H
A
E
H
A
A
There
was
a
guy
who
worked
with
a
few
years
ago
called
luke
pattini,
who
had
a
an
online
way
of
taking
what
was
in
the
google
sheet
and
rendering
it
in
a
sort
of
data
warrior
like
online
system,
where
you
could
then
look
at
the
structures
automatically,
and
I
think
we
kind
of
stopped
using
that
for
a
while.
It
was
very
useful.
We
kind
of
stopped
using
it,
because
people
find
it
difficult
to
understand,
but
yeah
I
mean
rendering
all
the
molecules
so
that
they
can
be
visually
inspected.
A
A
Well,
we
were
told
well
kind
of
yeah.
We
were
told
that
it
exists
in
pharma,
so
why
are
you
trying
to
build
it
in
open
source
mode,
basically
yeah
yeah?
That
was,
that
was
our
desire
to
build
a
bench
to
patient.
You
know
registration
system
for
compounds
and,
and
the
referee
said
well,
why
do
you
want
to
make
this
again
because
it
exists
in
big
pharma?